I was diagnosed with thyroid cancer in Nov., 1999. Surgery and radioactive iodine followed. In Dec., 2006, I found a lump in my neck that turned cancerous. Shortly thereafter, it was found to have metastasized throughout my body and to be untreatable and inoperable. I started a clinical trial with Sutent (sunitinib) since Apr., 2007.
In Nov., 2013, the tumors began growing again and I was removed from the Sutent Clinical Trial. I started a clinical trial taking of CEDIRANIB on 04/09/14.
Cancer video: Genetic basis of cancer hallmark; Thyroid cancer treatment variation; Vitamin D's confirmed roll in colon cancer
(Aug 18, 2011 - Insidermedicine) From Washington, research published in today’s issue of Science reveals the genetic basis of aneuploidy, or an abnormal number of chromosomes in cells. Aneuploidy is known to be a hallmark of cancer. Today’s research identifies the specific gene mutation that gives way to aneuploidy, thereby identifying a possible new direction for cancer therapy. From Ann Arbor, research published in the Journal of the American Medical Association highlights the variations in thyroid cancer treatment. Thyroid cancer is one of the 10 most common cancers in the United States. The findings show that beyond size and severity of tumour, additional unexplained hospital factors seemed to play a significant role in determining whether a patient was subjected to radioactive iodine treatment, leading the researchers to call for better standardized treatment guidelines. From Barcelona, research published in PLoS One has confirmed the key role of vitamin D in hindering colon cancer progression. The findings affirm that chronic vitamin D deficiency represents a risk factor for aggressive colon tumours.